Smart jab can shrink head and neck cancer tumours within six weeks, trial finds

19 octobre 2025 | Andrew Gregory Health editor
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers Doctors have hailed “incredibly encouraging” trial results that show a triple-action smart jab can shrink tumours in head and neck cancer patients within six weeks. Head and neck (…)
 Site référencé:  The Guardian (South&CentralAsia)

The Guardian (South&CentralAsia) 

Expanding variety at Royal Albert Hall | Brief letters
19/10/2025
Nicolas Sarkozy to enter prison for criminal conspiracy over Libyan funding
19/10/2025
Martin Mansergh obituary
19/10/2025
William Haggas criticises Oisin Murphy for ‘professional foul’ riding tactics
19/10/2025
Tom Gauld on limited editions – cartoon
19/10/2025
Houthi rebels detain 20 UN staff in Yemen
19/10/2025